Neogen Share Price Today

Neogen sees Antipodean review of Zoetis deal ending in early 2027

Regulatory review of Neogen's genomics sale to Zoetis in Australia and New Zealand is expected to end in early 2027. Zoetis has offered to divest certain Australian assets to facilitate regulatory approval. The update pertains to the ongoing merger between the two life sciences companies.

Pomerantz investigates Neogen after FDA warning links product to horse deaths

Pomerantz LLP is investigating Neogen Corporation for potential securities fraud. FDA issued a warning letter linking Neogen Vet HYCOAT to at least 20 horse deaths. Neogen stock fell 7.22% to $12.73 per share on September 29, 2026. The company initiated a voluntary recall of the product in late January 2026.

Law Offices of Howard G. Smith probes Neogen over FDA warning

Law Offices of Howard G. Smith joins Glancy Prongay and Frank R. Cruz in investigating Neogen Corporation. FDA warning linked Hycoat product to at least 20 horse deaths, the largest such incident for an FDA-regulated veterinary product. Neogen shares fell 7.22% to $12.73 on September 29, 2026, following the FDA announcement. Investigations focus on potential federal securities law violations regarding disclosure of safety issues.

Neogen targets 30% EBITDA margin and double-digit growth by FY31

Neogen targets 30% adjusted EBITDA margin and high-single-digit to low-double-digit revenue growth by FY31. Q1 core revenue rose 8.1% with adjusted EBITDA of $41.6 million beating $37 million expectation. R&D investment to increase 50% in FY27, targeting 5% of revenue by FY31. Petrifilm manufacturing transfer to Lansing facility begins November 2026, tripling capacity.

Neogen Q1FY27 Results: Revenue up 6.5% to $222.8M, net loss of $11.9M

Revenue rose 6.5% YoY to $222.8 million, beating consensus estimates. Net loss of $11.9 million due to absence of prior-year divestiture gains. Adjusted EBITDA climbed 17.2% to $41.6 million with margin expanding to 18.7%. FY27 revenue guidance raised to $885-$890 million; adjusted EBITDA to $181-$183 million.

Neogen invests in Hinalea to advance AI food safety imaging

Neogen Corporation made an equity investment in Hinalea Imaging Corp. Collaboration focuses on developing hyperspectral imaging for food safety. Goal is to automate inspection workflows and speed up result interpretation. Partnership builds on joint evaluation work conducted since 2025.